NCT06204250View on ClinicalTrials.gov

A Study to Assess Safety and Tolerability of GS1-144 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

86

Participants

Timeline

Start Date

February 27, 2024

Primary Completion Date

December 19, 2024

Study Completion Date

December 19, 2024

Conditions

Vasomotor SymptomsAdult Healthy Volunteers

Interventions

DRUG

GS1-144

Oral tablets.

DRUG

Placebo

Matching placebo tablets.

Trial Locations (1)

WA 6027

Linear Clinical Research, Perth

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Syneos Health

OTHER

lead

Changchun GeneScience Pharmaceutical Co., Ltd.

INDUSTRY